The impact of insulin-independent, glucagon-induced suppression of total ghrelin on satiety in obesity and type 1 diabetes mellitus.

Arafat AM, Weickert MO, Adamidou A, Otto B, Perschel FH, Spranger J, Möhlig M, Pfeiffer AF

The Journal of clinical endocrinology and metabolism21 Aug 2013Cited by 19 (Europe PMC)

PMID23966238DOI10.1210/jc.2013-1635PepBankPUB-23966238

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with T1DM, glucagon increased satiety index versus placebo (P < .001).
In plain wordsIn patients with type 1 diabetes, glucagon increased satiety more than placebo.
Peptide
Glucagon
Outcome
IncreaseSatiety in T1DM
Study
n = 13
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
As compared with placebo, glucagon significantly increased satiety index in T1DM and in LP (P < .001) but failed to induce satiety in OP (P = .152).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623801
02HumanNon-randomized trialEfficacy outcome
In healthy lean participants, glucagon increased satiety index versus placebo (P < .001).
In plain wordsIn healthy lean participants, glucagon increased satiety more than placebo.
Peptide
Glucagon
Outcome
IncreaseSatiety in lean participants
Study
n = 13
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
As compared with placebo, glucagon significantly increased satiety index in T1DM and in LP (P < .001) but failed to induce satiety in OP (P = .152).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623802
03HumanNon-randomized trialMechanism
In patients with T1DM, total ghrelin decreased after glucagon (P < .01).
In plain wordsIn patients with type 1 diabetes, total ghrelin decreased after glucagon.
Peptide
Glucagon
Outcome
DecreaseTotal ghrelin in T1DM
Study
n = 13
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
Total ghrelin significantly decreased after glucagon administration in all study groups (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623804
04HumanNon-randomized trialMechanism
In healthy lean participants, total ghrelin decreased after glucagon (P < .01).
In plain wordsIn healthy lean participants, total ghrelin decreased after glucagon.
Peptide
Glucagon
Outcome
DecreaseTotal ghrelin in lean participants
Study
n = 13
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
Total ghrelin significantly decreased after glucagon administration in all study groups (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623806
05HumanNon-randomized trialMechanism
In healthy lean participants, acyl-ghrelin decreased after glucagon (P < .01).
In plain wordsIn healthy lean participants, acyl-ghrelin decreased after glucagon.
Peptide
Glucagon
Outcome
DecreaseAcyl-ghrelin in lean participants
Study
n = 13
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
Similarly, acyl-ghrelin significantly decreased in LP (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623807
06HumanNon-randomized trialMechanism
In patients with T1DM, acyl-ghrelin increased after glucagon (P < .01).
In plain wordsIn patients with type 1 diabetes, acyl-ghrelin increased after glucagon.
Peptide
Glucagon
Outcome
IncreaseAcyl-ghrelin in T1DM
Study
n = 13
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
However, acyl-ghrelin concentrations showed no change in OP (P = .248) and even increased substantially in T1DM (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623809
07HumanNon-randomized trialEfficacy outcome
In participants with obesity, glucagon did not significantly increase satiety index versus placebo (P = .152).
In plain wordsIn participants with obesity, glucagon did not significantly increase satiety compared with placebo.
Peptide
Glucagon
Outcome
No significant changeSatiety in obesity
Study
n = 11
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
As compared with placebo, glucagon significantly increased satiety index in T1DM and in LP (P < .001) but failed to induce satiety in OP (P = .152).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623803
08HumanNon-randomized trialMechanism
In obese participants, total ghrelin decreased after glucagon (P < .01).
In plain wordsIn participants with obesity, total ghrelin decreased after glucagon.
Peptide
Glucagon
Outcome
DecreaseTotal ghrelin in obesity
Study
n = 11
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
Total ghrelin significantly decreased after glucagon administration in all study groups (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623805
09HumanNon-randomized trialMechanism
In obese participants, acyl-ghrelin did not change after glucagon (P = .248).
In plain wordsIn participants with obesity, acyl-ghrelin did not change after glucagon.
Peptide
Glucagon
Outcome
No significant changeAcyl-ghrelin in obesity
Study
n = 11
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Source sentences
Summary
However, acyl-ghrelin concentrations showed no change in OP (P = .248) and even increased substantially in T1DM (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623808
10HumanObservational studyMechanism
Across study groups after glucagon, acyl-ghrelin changes correlated positively with nonesterified fatty acid changes (r = 0.31-0.43; P < .01).
In plain wordsAfter glucagon, acyl-ghrelin changes were positively linked to fatty acid changes in all participant groups.
Peptide
Glucagon
Outcome
IncreaseAcyl-ghrelin and fatty acid correlation
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Correlation (r) of acyl-ghrelin change with NEFA change
0.31 to 0.43 r
all groups after glucagon
Source sentences
Summary
Changes in acyl-ghrelin correlated positively with changes in nonesterified fatty acid concentrations in all groups (r = 0.31-0.43; P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration
Report a problemFND-2396623810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT00929812

Glucagon Modulation of Ghrelin Secretion

Charite University, Berlin, Germanyn = 38Jun 2006 to est. Dec 2009

Healthy Subjects · Obesity · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 30 Jun 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.